Provided is an organic metal complex having a structure represented by the following general formula (1):

ML.sub.mL.sub.n(1)

where: M represents a metal atom selected from Ir, Pt, Rh, Os, and Zn; L and L, which are different from each other, each represent a bidentate ligand; m represents an integer of 1 to 3 and n represents an integer of 0 to 2, provided that m+n is 3; a partial structure ML.sub.m represents a structure represented by the following general formula (2):

##STR00001##

and a partial structure ML.sub.n represents a structure including a monovalent bidentate ligand.

Provided is an organic metal complex having a structure represented by the following general formula (1):

ML.sub.mL.sub.n(1)

where: M represents a metal atom selected from Ir, Pt, Rh, Os, and Zn; L and L, which are different from each other, each represent a bidentate ligand; m represents an integer of 1 to 3 and n represents an integer of 0 to 2, provided that m+n is 3; a partial structure ML.sub.m represents a structure represented by the following general formula (2):

##STR00001##

and a partial structure ML.sub.n represents a structure including a monovalent bidentate ligand.

Provided is an organic metal complex having a structure represented by the following general formula (1):

ML.sub.mL.sub.n(1)

where: M represents a metal atom selected from Ir, Pt, Rh, Os, and Zn; L and L, which are different from each other, each represent a bidentate ligand; m represents an integer of 1 to 3 and n represents an integer of 0 to 2, provided that m+n is 3; a partial structure ML.sub.m represents a structure represented by the following general formula (2):

##STR00001##

and a partial structure ML.sub.n represents a structure including a monovalent bidentate ligand.

Provided is a method for preparing 2-hydroxy-4-(2, 3-disubstituted benzyloxy)-5-substituted benzaldehyde derivative represented by formula (I). The method comprises the following steps: (1) preparing 3-aryl-2-substituted toluene derivative 2 by using 3-iodo-2-substituted toluene derivative 1 and aryl boronic acid 5 or aryl boronate as starting materials; (2) preparing a benzyl halide derivative 3 by using 3-aryl-2-substituted toluene derivative 2 as starting materials; and (.sup.3) preparing 4-(2, 3-disubstituted benzyloxy)-2-hydroxy-5-substituted benzaldehyde derivative (I) by using benzyl halide derivative 3 and 2,4-dihydroxy-5-substituted benzaldehyde 6.

##STR00001##

Provided is a method for preparing 2-hydroxy-4-(2, 3-disubstituted benzyloxy)-5-substituted benzaldehyde derivative represented by formula (I). The method comprises the following steps: (1) preparing 3-aryl-2-substituted toluene derivative 2 by using 3-iodo-2-substituted toluene derivative 1 and aryl boronic acid 5 or aryl boronate as starting materials; (2) preparing a benzyl halide derivative 3 by using 3-aryl-2-substituted toluene derivative 2 as starting materials; and (.sup.3) preparing 4-(2, 3-disubstituted benzyloxy)-2-hydroxy-5-substituted benzaldehyde derivative (I) by using benzyl halide derivative 3 and 2,4-dihydroxy-5-substituted benzaldehyde 6.

##STR00001##

Methods of CH bond fluorination using non-heme manganese catalyst are described herein. For example, a method comprises providing a reaction mixture including a non-heme manganese catalyst, a substrate comprising an sp.sup.3 CH bond and a fluorinating agent and converting the sp.sup.3 CH bond to a CF bond in the presence of the non-heme manganese catalyst or a derivative thereof.

Methods of CH bond fluorination using non-heme manganese catalyst are described herein. For example, a method comprises providing a reaction mixture including a non-heme manganese catalyst, a substrate comprising an sp.sup.3 CH bond and a fluorinating agent and converting the sp.sup.3 CH bond to a CF bond in the presence of the non-heme manganese catalyst or a derivative thereof.

Methods of CH bond fluorination using non-heme manganese catalyst are described herein. For example, a method comprises providing a reaction mixture including a non-heme manganese catalyst, a substrate comprising an sp.sup.3 CH bond and a fluorinating agent and converting the sp.sup.3 CH bond to a CF bond in the presence of the non-heme manganese catalyst or a derivative thereof.

The present invention discloses a nicotinyl alcohol ether derivative, a preparation method therefor, and a pharmaceutical composition and uses thereof. Specifically, the invention relates to nicotinyl alcohol ether derivatives represented by formula (I), a pharmaceutically-acceptable salt thereof, a stereoisomer thereof, a preparation method therefor, a pharmaceutical composition containing the one or more compounds, and uses of the compounds in treating diseases related to PD-1/PD-L1 signal channels, such as cancers, infectious diseases and autoimmune diseases.

##STR00001##

The present invention discloses a nicotinyl alcohol ether derivative, a preparation method therefor, and a pharmaceutical composition and uses thereof. Specifically, the invention relates to nicotinyl alcohol ether derivatives represented by formula (I), a pharmaceutically-acceptable salt thereof, a stereoisomer thereof, a preparation method therefor, a pharmaceutical composition containing the one or more compounds, and uses of the compounds in treating diseases related to PD-1/PD-L1 signal channels, such as cancers, infectious diseases and autoimmune diseases.

##STR00001##